Display options
Share it on

Oncotarget. 2017 Dec 22;9(4):4985-4997. doi: 10.18632/oncotarget.23577. eCollection 2018 Jan 12.

The microtubule-associated protein PRC1 is a potential therapeutic target for lung cancer.

Oncotarget

Steffen Hanselmann, Patrick Wolter, Jonas Malkmus, Stefan Gaubatz

Affiliations

  1. Theodor Boveri Institute, Biocenter, University of Wuerzburg and Comprehensive Cancer Center Mainfranken, University of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.

PMID: 29435157 PMCID: PMC5797028 DOI: 10.18632/oncotarget.23577

Abstract

In this study, we investigated whether proteins that are involved in cytokinesis are potential targets for therapy of lung cancer. We find that the microtubule-associated protein PRC1 (protein required for cytokinesis 1), which plays a key role in organizing anti-parallel microtubule in the central spindle in cytokinesis, is overexpressed in lung cancer cell lines compared to normal cells. Increased expression of PRC1 is correlated with a poor prognosis of human lung adenocarcinoma patients. Lentiviral delivered, inducible RNAi of PRC1 demonstrated that proliferation of lung cancer cell lines strongly depends on PRC1. Significantly, we also show that PRC1 is required for tumorigenesis

Keywords: PRC1; lung adenocarcinoma; mitotic kinesins; therapeutic target

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Cell. 2012 Apr 27;149(3):642-55 - PubMed
  2. Ther Adv Med Oncol. 2015 May;7(3):170-80 - PubMed
  3. Cancer Res. 2009 May 1;69(9):4073-80 - PubMed
  4. Nat Genet. 2006 Sep;38(9):1043-8 - PubMed
  5. Genes Dev. 2001 Dec 15;15(24):3243-8 - PubMed
  6. Nat Rev Drug Discov. 2014 Nov;13(11):828-51 - PubMed
  7. Cell. 1997 Mar 7;88(5):593-602 - PubMed
  8. Cancer Cell. 2009 Oct 6;16(4):347-58 - PubMed
  9. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 - PubMed
  10. Nat Rev Mol Cell Biol. 2009 Jan;10(1):9-20 - PubMed
  11. Oncotarget. 2017 Feb 14;8(7):11160-11172 - PubMed
  12. EMBO J. 2007 Jan 10;26(1):144-57 - PubMed
  13. Nat Rev Cancer. 2012 Jul 24;12 (8):527-39 - PubMed
  14. Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 - PubMed
  15. Oncogene. 2017 Jan 5;36(1):110-121 - PubMed
  16. Genes Dev. 2000 Apr 15;14(8):994-1004 - PubMed
  17. Cell. 2009 May 29;137(5):835-48 - PubMed
  18. J Cell Sci. 2012 Aug 1;125(Pt 15):3495-500 - PubMed
  19. Nat Med. 2008 Dec;14(12):1351-6 - PubMed
  20. Gut. 2016 Sep;65(9):1522-34 - PubMed
  21. Cell Rep. 2015 Sep 1;12(9):1483-96 - PubMed
  22. Curr Biol. 2010 May 11;20(9):880-5 - PubMed
  23. Nat Rev Cancer. 2013 Aug;13(8):585-95 - PubMed
  24. Mol Cancer. 2017 Jun 24;16(1):108 - PubMed
  25. Pharmacogenomics. 2014 Aug;15(11):1507-18 - PubMed
  26. Nat Protoc. 2006;1(1):241-5 - PubMed
  27. Cell. 2009 Mar 6;136(5):823-37 - PubMed
  28. Cancer Cell. 2011 Jun 14;19(6):691-2 - PubMed
  29. Oncotarget. 2016 Dec 27;7(52):87323-87341 - PubMed
  30. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  31. Genes Dev. 2008 Aug 15;22(16):2189-203 - PubMed
  32. Nat Protoc. 2009;4(7):1064-72 - PubMed
  33. Cancer Cell. 2013 Jan 14;23(1):121-8 - PubMed
  34. Cancer Sci. 2007 Feb;98 (2):174-81 - PubMed
  35. J Clin Invest. 2012 Apr;122(4):1138-43 - PubMed
  36. Breast Cancer Res Treat. 2010 Oct;123(3):725-31 - PubMed
  37. Annu Rev Cell Dev Biol. 2012;28:29-58 - PubMed

Publication Types